The impact of multiparametric pelvic magnetic resonance imaging on risk stratification in patients with localized prostate cancer

Urology

Volumn 84, Issue 1, 2014, Pages 132-137

  Marcus, David M ^a,b   Rossi, Peter J ^a,b   Nour, Sherif G ^a,b   Jani, Ashesh B ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GADOBENATE DIMEGLUMINE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BRACHYTHERAPY; CANCER HORMONE THERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURGERY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIFFUSION WEIGHTED IMAGING; DIGITAL RECTAL EXAMINATION; DISTANT METASTASIS; EXTERNAL BEAM RADIOTHERAPY; GLEASON SCORE; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTERMEDIATE RISK PATIENT; INTERMETHOD COMPARISON; LOW RISK PATIENT; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; MULTIPARAMETRIC PELVIC MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PELVIS RADIOGRAPHY; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE BIOPSY; PROSTATECTOMY; TIME TO TREATMENT; TUMOR BIOPSY; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK ASSESSMENT;

EID: 84903720592     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2014.03.012     Document Type: Article

References (29)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2013 CA Cancer J Clin 63 2013 11 30
2. D. Scherr, P.W. Swindle, and P.T. Scardino et al. National Comprehensive Cancer Network guidelines for the management of prostate cancer Urology 61 2003 14 24
3. T. Hambrock, C. Hoeks, and C. Hulsbergen-van de Kaa et al. Prospective assessment of prostate cancer aggressiveness using 3-T diffusion-weighted magnetic resonance imaging-guided biopsies versus a systematic 10-core transrectal ultrasound prostate biopsy cohort Eur Urol 61 2012 177 184
4. D.M. Somford, T. Hambrock, and C.A. Hulsbergen-van de Kaa et al. Initial experience with identifying high-grade prostate cancer using diffusion-weighted MR imaging (DWI) in patients with a Gleason score ≤3 + 3 = 6 upon schematic TRUS-guided biopsy: a radical prostatectomy correlated series Invest Radiol 47 2012 153 158
5. J.V. Hegde, M.H. Chen, and R.V. Mulkern et al. Preoperative 3-Tesla multiparametric endorectal magnetic resonance imaging findings and the odds of upgrading and upstaging at radical prostatectomy in men with clinically localized prostate cancer Int J Radiat Oncol Biol Phys 85 2013 e101 e107
6. D.M. Somford, E.H. Hamoen, and J.J. Futterer et al. The predictive value of endorectal 3-Tesla multiparametric MRI for extraprostatic extension in low-, intermediate and high-risk prostate cancer patients J Urol 190 2013 1728 1734
7. F. Cornud, T. Flam, and L. Chauveinc et al. Extraprostatic spread of clinically localized prostate cancer: factors predictive of pT3 tumor and of positive endorectal MR imaging examination results Radiology 224 2002 203 210
8. A.V. D'Amico, R. Whittington, and S.B. Malkowicz et al. Critical analysis of the ability of the endorectal coil magnetic resonance imaging scan to predict pathologic stage, margin status, and postoperative prostate-specific antigen failure in patients with clinically organ-confined prostate cancer J Clin Oncol 14 1996 1770 1777
9. A.E. Maxwell Comparing the classification of subjects by two independent judges Br J Psychiatry 116 1970 651 655
10. A. Stuart A test for homogeneity of the marginal distributions in a two way classification Biometrika 42 1955 412 416
11. M. Bolla, H. van Poppel, and B. Tombal et al. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911) Lancet 380 2012 2018 2027
12. I.M. Thompson, C.M. Tangen, and J. Paradelo et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial J Urol 181 2009 956 962
13. T. Wiegel, D. Bottke, and U. Steiner et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95 J Clin Oncol 27 2009 2924 2930
14. I.M. Thompson, R.K. Valicenti, and P. Albertsen et al. Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO Guideline J Urol 190 2013 441 449
15. A.V. D'Amico, M.H. Chen, and A.A. Renshaw et al. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial JAMA 299 2008 289 295
16. M. Bolla, T.M. de Reijke, and G. Van Tienhoven et al. Duration of androgen suppression in the treatment of prostate cancer N Engl J Med 360 2009 2516 2527
17. J.W. Denham, A. Steigler, and D.S. Lamb et al. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial Lancet Oncol 12 2011 451 459
18. G.E. Hanks, T.F. Pajak, and A. Porter et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02 J Clin Oncol 21 2003 3972 3978
19. C.U. Jones, D. Hunt, and D.G. McGowan et al. Radiotherapy and short-term androgen deprivation for localized prostate cancer N Engl J Med 365 2011 107 118
20. L. Wang, H. Hricak, and M.W. Kattan et al. Prediction of organ-confined prostate cancer: incremental value of MR imaging and MR spectroscopic imaging to staging nomograms Radiology 238 2006 597 603
21. A. Shukla-Dave, H. Hricak, and O. Akin et al. Preoperative nomograms incorporating magnetic resonance imaging and spectroscopy for prediction of insignificant prostate cancer BJU Int 109 2012 1315 1322
22. B. Turkbey, H. Mani, and O. Aras et al. Prostate cancer: can multiparametric MR imaging help identify patients who are candidates for active surveillance? Radiology 268 2013 144 152
23. A. Pettersson, R.E. Graff, and S.R. Bauer et al. The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis Cancer Epidemiol Biomarkers Prev 21 2012 1497 1509
24. D.W. Lin, L.F. Newcomb, and E.C. Brown et al. Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study Clin Cancer Res 19 2013 2442 2450
25. C. Whelan, M. Kawachi, and D.D. Smith et al. Expressed prostatic secretion biomarkers improve stratification of NCCN active surveillance candidates: performance of secretion capacity and TMPRSS2:ERG models J Urol 191 2014 220 226
26. R.B. Nagle, A.M. Algotar, and C.C. Cortez et al. ERG overexpression and PTEN status predict capsular penetration in prostate carcinoma Prostate 73 2013 1233 1240
27. A. Sciarra, V. Panebianco, and S. Cattarino et al. Multiparametric magnetic resonance imaging of the prostate can improve the predictive value of the urinary prostate cancer antigen 3 test in patients with elevated prostate-specific antigen levels and a previous negative biopsy BJU Int 110 2012 1661 1665
28. N.K. Yerram, D. Volkin, and B. Turkbey et al. Low suspicion lesions on multiparametric magnetic resonance imaging predict for the absence of high-risk prostate cancer BJU Int 110 2012 E783 E788
29. A.N. Ali, P.J. Rossi, and K.D. Godette et al. Impact of magnetic resonance imaging on computed tomography-based treatment planning and acute toxicity for prostate cancer patients treated with intensity modulated radiation therapy Pract Radiat Oncol 3 2013 e1 e9